← Leaderboards
Soumitro Pal
Children'S Hospital Boston
$7,486,161
Attributed
$7,486,161
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $904.5K · FY2005–22$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$7,486,161 · 7
By mechanism
R01$5,831,292 · 3
R21$848,769 · 2
K01$629,100 · 1
R03$177,000 · 1
Top collaborators
No co-investigators on record.
Most similar at Children'S Hospital Boston
Same institution · by research overlap
- David Michael Briscoe$31,770,341
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsTumor GrowthMediatingLeadSignal TransductionImmunosuppressive AgentsRenal Cell CarcinomaOrgan TransplantationRenal CarcinomaEndothelial CellsSolidTransplant RecipientsPathway InteractionsTumorKidneyGrowthEventKidney NeoplasmsAllograftingOverexpressionCancer TransplantationLigandsMigrationAngiogenesis
Grant awards (26)
Protective role of Honokiol in preventing c-Met-induced post-transplantation cancer$396,790
R01 · FY2022 · CA · contact PI
Protective role of Honokiol in preventing c-Met-induced post-transplantation cancer$404,888
R01 · FY2021 · CA · contact PI
Protective role of Honokiol in preventing c-Met-induced post-transplantation cancer$404,888
R01 · FY2020 · CA · contact PI
Novel Role(s) of Nrf2 in the Growth of Post-Transplantation Cancer$404,888
R01 · FY2020 · CA · contact PI
Protective role of Honokiol in preventing c-Met-induced post-transplantation cancer$398,735
R01 · FY2019 · CA · contact PI
Novel Role(s) of Nrf2 in the Growth of Post-Transplantation Cancer$392,740
R01 · FY2019 · CA · contact PI
CXCR3-B-mediated novel growth-inhibitory signals in breast cancer cells$88,500
R03 · FY2019 · CA · contact PI
Protective role of Honokiol in preventing c-Met-induced post-transplantation cancer$411,068
R01 · FY2018 · CA · contact PI
Novel Role(s) of Nrf2 in the Growth of Post-Transplantation Cancer$404,888
R01 · FY2018 · CA · contact PI
CXCR3-B-mediated novel growth-inhibitory signals in breast cancer cells$88,500
R03 · FY2018 · CA · contact PI
Novel Role(s) of Nrf2 in the Growth of Post-Transplantation Cancer$411,185
R01 · FY2017 · CA · contact PI
Novel Role(s) of Nrf2 in the Growth of Post-Transplantation Cancer$411,185
R01 · FY2016 · CA · contact PI
Novel Role of Honokiol in Preventing Cancer during Immune Suppression$198,336
R21 · FY2016 · CA · contact PI
Novel Role of Honokiol in Preventing Cancer during Immune Suppression$236,488
R21 · FY2015 · CA · contact PI
Novel Therapeutic Targets For Calcineurin Inhibitor-Induced And mTOR-Mediated Can$185,570
R21 · FY2014 · CA · contact PI
Pathophysiology of Post-Transplantation Cancer$329,206
R01 · FY2013 · CA · contact PI
Novel Therapeutic Targets For Calcineurin Inhibitor-Induced And mTOR-Mediated Can$228,375
R21 · FY2013 · CA · contact PI
Pathophysiology of Post-Transplantation Cancer$350,219
R01 · FY2012 · CA · contact PI
Pathophysiology of Post-Transplantation Cancer$374,745
R01 · FY2011 · CA · contact PI
Pathophysiology of Post-Transplantation Cancer$383,116
R01 · FY2010 · CA · contact PI
Pathophysiology of Post-Transplantation Cancer$352,751
R01 · FY2009 · CA · contact PI
VEGF And Renal Inflammation$125,820
K01 · FY2007 · DK · contact PI
VEGF And Renal Inflammation$125,820
K01 · FY2006 · DK · contact PI
VEGF And Renal Inflammation$125,820
K01 · FY2005 · DK
VEGF And Renal Inflammation$125,820
K01 · FY2004 · DK
VEGF And Renal Inflammation$125,820
K01 · FY2003 · DK